NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study Fifteen CNS MZBCLs ...
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non ...
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate. The potential Food and Drug ...
Results from a clinical trial conducted by researchers at the National Institutes of Health (NIH) show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a ...
Primary thyroid lymphoma (PTL) is an uncommon thyroid malignancy, representing approximately 1–5% of thyroid cancers and 2.5–7% of extranodal lymphomas. Predominantly of B‐cell origin, PTL most ...
Please provide your email address to receive an email when new articles are posted on . The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results